A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
- 1 May 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 25 (5), 555-561
- https://doi.org/10.1038/nbt1303
Abstract
Nature Biotechnology journal featuring biotechnology articles and science research papers of commercial interest in pharmaceutical, medical, and environmental sciences.Keywords
This publication has 22 references indexed in Scilit:
- Immunogenicity of xenopeptide hormone therapiesPeptides, 2006
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe DiseasePEDIATRICS, 2004
- Clinical impact of antibody formation to botulinum toxin A in childrenAnnals of Neurology, 2004
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinThe New England Journal of Medicine, 2002
- Facilitation of the Growth Promoting Effect of Growth Hormone (GH) by an Antibody to Methionyl-GHJournal of Pediatric Endocrinology and Metabolism, 1995
- OKT3 MONOCLONAL ANTIBODY PLASMA LEVELS DURING THERAPY AND THE SUBSEQUENT DEVELOPMENT OF HOST ANTIBODIES TO OKT3Transplantation, 1986
- ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSIONTransplantation, 1986
- INSULIN-I131 METABOLISM IN HUMAN SUBJECTS: DEMONSTRATION OF INSULIN BINDING GLOBULIN IN THE CIRCULATION OF INSULIN TREATED SUBJECTS 1JCI Insight, 1956